The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting in May 2026, Fry will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee. This nomination is significant for Lonza, the world's largest contract development and manufacturing organization dedicated to healthcare, as it seeks to enhance its governance and organizational capabilities during a period of industry transformation.
Fry brings deep pharmaceutical industry experience, having spent more than three decades at Eli Lilly and Company, where he ultimately served as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, he led large-scale organizational transformation, shaped high-performance cultures, and helped navigate the company through significant change. His extensive international experience and strong track record in organizational governance, succession planning, and people strategy development represent a valuable complementary fit with the existing Board members.
Jean-Marc Huet, Chairman of the Board at Lonza, stated that Fry will play an important role in helping develop and embed the company's performance culture. This will support Lonza's ambition to attract and retain world-leading talent and bring its high-performing teams to the next level. For a company that generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025, maintaining a competitive edge in talent management is crucial. Lonza's global team of approximately 20,000 colleagues works alongside pharma and biotech companies across five continents to turn breakthrough innovations into viable therapies, enabling customers to bring life-saving and life-enhancing treatments to patients worldwide.
The nomination matters because it signals Lonza's commitment to strengthening its governance framework and organizational resilience. As a major player in the CDMO sector, Lonza's ability to navigate complex regulatory environments, manage global operations, and foster innovation depends heavily on effective board oversight and corporate culture. Fry's appointment to both the People and Governance Committee and the Audit and Compliance Committee suggests a focus on these critical areas. Investors and industry observers can find more information about Lonza at https://www.lonza.com.
For the broader pharmaceutical and biotech industry, this move highlights the increasing importance of governance expertise in CDMOs that serve as essential partners in drug development and manufacturing. As companies like Lonza handle more complex therapies and global supply chains, robust compliance and people strategies become competitive advantages. The nomination also reflects the trend of pharmaceutical veterans bringing their operational experience to service providers in the healthcare ecosystem. While the election is pending until the 2026 AGM, the nomination itself sets a direction for Lonza's leadership priorities in the coming years.
